Monoclonal antibodies in the treatment of thyroid eye disease

Cheredanova V.R.; Poteshkin Y.E.

doi:https://doi.org/10.17116/oftalma2021137041116

Close metadata

Recommended articles:

Lower eyelid retraction after inferior rectus recession in thyroid eye disease. Russian Annals of Ophthalmology. 2025;(2):101-105

Outcomes of modified lateral orbital wall decompression using ultrasonic bone removal. Russian Annals of Ophthalmology. 2025;(4):21-28

Endoscopic assistance in deep lateral orbital wall decompression. Russian Annals of Ophthalmology. 2025;(5):23-28

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

Clinical efficacy of dupilumab monoclonal antibody in the treatment of recurrent severe chronic rhinosinusitis with nasal polyps without bronchial asthma. Russian Rhinology. 2025;(4):32-37

Abstract:

Thyroid eye disease (TED) is an autoimmune condition affecting extraocular muscles and orbital fat that is most often a manifestation of the Graves’ disease or Hashimoto thyroiditis. This disease significantly worsens the quality of life of patients, and therefore requires the use of effective treatment methods. Traditional therapy involves glucocorticosteroids and x-rays aimed at reducing the inflammatory process, rather than proptosis and diplopia, while targeted therapy is better able to influence the clinical course of the disease. The review presents a modern understanding of the pathogenesis of TED and analysis of clinical studies concerning the use of monoclonal antibodies for its treatment.

Keywords:

thyroid eye disease

TED

Graves’ ophthalmopathy

Graves’ disease

monoclonal antibodies

Authors:

Cheredanova V.R.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Poteshkin Y.E.

Pirogov Russian National Research Medical University

Received:

01.06.2020

Accepted:

06.07.2020

Close metadata

References:

Petunina NA, Truhina LV, Martirosyan NS. Endocrine ophthalmopathy: state-of-the-art approaches. Problemy endokrinologii. 2012;58(6):24-32. (In Russ.). https://doi.org/10.14341/probl201258624-32
Taskina ES, Harinceva SV, Harincev VV, Serkin DM. New opportunities in endocrine ophthalmopathy diagnostics (review). Klinicheskaya i eksperimental’naya tireoidologiya. 2017;13(3):20-28. (In Russ.). https://doi.org/10.14341/ket2017320-28
Wang Y, Patel A, Douglas RS. Thyroid eye disease: How a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318. https://doi.org/10.2147/TCRM.S193018
Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134-142. https://doi.org/10.1016/S2213-8587(16)30046-8
Genere N, Stan MN. Current and Emerging Treatment Strategies for Graves’ Orbitopathy. Drugs. 2019;79(2):109-124. https://doi.org/10.1007/s40265-018-1045-9
Şahlı E, Gündüz K. Thyroid-associated ophthalmopathy. Turk Oftalmoloiji Derg. 2017;47(2):94-105. https://doi.org/10.4274/tjo.80688
Perros P, Hegedüs L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12(1):72. https://doi.org/10.1186/s13023-017-0625-1
Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018;11(11):CD012984. https://doi.org/10.1002/14651858.cd012984.pub2
Sviridenko NYu, Sheremeta MS, Grusha YO. International Symposium for Thyroid Eye Disease (June 2016, London). Klinicheskaya i eksperimental’naya tireoidologiya. 2016;12(3):12-19. (In Russ.). https://doi.org/10.14341/ket2016312-19
Kumari R, Chandra Saha B. Advances in the management of thyroid eye diseases: An overview. Int Ophthalmol. 2018;38(5):2247-2255. https://doi.org/10.1007/s10792-017-0694-0
Smith TJ, Janssen JAMJL. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2018;40(1):236-267. https://doi.org/10.1210/er.2018-00066
Mohyi M, Smith TJ. 40 years of IGF1: IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018;61(1):29-43. https://doi.org/10.1530/JME-17-0276
Krajewska-Węglewicz L, Radomska-Leśniewska DM, Dorobek M, et al. Update on pathogenesis and immunology of Graves’ ophthalmopathy. Cent Eur J Immunol. 2018;43(4):458-465. https://doi.org/10.5114/ceji.2018.81360
Strianese D, Rossi F. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy. Eye. 2019;33(2):191-199. https://doi.org/10.1038/s41433-018-0315-9
Kotwal A, Stan MN. Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy. Horm Metab Res. 2018;50(12):871-886. https://doi.org/10.1055/a-0739-8134
Zhu W, Ye L, Shen L, et al. A prospe ctive, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves’ ophthalmopathy. J Clin Endocrinol Metab. 2014;99(6):1999-2007. https://doi.org/10.1210/jc.2013-3919
Vannucchi G, Covelli D, Campi I, et al. The therapeutic outcome of intravenous steroid therapy for active Graves’ orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2014;170(1):55-61. https://doi.org/10.1530/EJE-13-0611
Bartalena L. Glucocorticoids for Graves’ Ophthalmopathy: How and When. J Clin Endocrinol Metab. 2005;90(9):5497-5499. https://doi.org/10.1210/jc.2005-1553
Gorman CA, Garrity JA, Fatourechi V, et al. A Prospective, Randomized, Double-blind, Placebo-controlled Study of Orbital Radiotherapy for Graves’ Ophthalmopathy. Ophthalmology. 2020;127:160-171. https://doi.org/10.1016/j.ophtha.2020.01.031
Stan MN, Garrity JA, Leon BGC, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441. https://doi.org/10.1210/jc.2014-2572
Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2): 422-431. https://doi.org/10.1210/jc.2014-3014
Stan M, Salvi M. Management of endocrine disease: Rituximab therapy for Graves’ orbitopathy — lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):101-109. https://doi.org/10.1530/EJE-16-0552
Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, Tam KW. Efficacy and Safety of Rituximab for the Treatment of Graves’ Orbitopathy: A Meta-analysis of Randomized Controlled Trials. Pharmacotherapy. 2018;38(5):503-510. https://doi.org/10.1002/phar.2111
Wang C, Ning Q, Jin K, Xie J, Ye J. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmol. 2018;18(1):46. https://doi.org/10.1186/s12886-018-0679-4
Du Pasquier-Fediaevsky L, Andrei S, Berche M, Leenhardt L, Héron E, Rivière S. Low-Dose Rituximab for Active Moderate to Severe Graves’ Orbitopathy Resistant to Conventional Treatment. Ocul Immunol Inflamm. 2019;27(5):844-850. https://doi.org/10.1080/09273948.2018.1453078
Karasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017;68(5):498-504. https://doi.org/10.5603/EP.a2017.0040
Li J, Xiao Z, Hu X, et al. The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy Patients. Pharmacology. 2017;99(3-4):144-152. https://doi.org/10.1159/000453618
Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(11):4291-4299. https://doi.org/10.1210/jc.2013-1804
Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye. 2019;33(2):183-190. https://doi.org/10.1038/s41433-018-0321-y
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761. https://doi.org/10.1056/NEJMoa1614949
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. https://doi.org/10.1056/NEJMoa1910434
Sy A, Eliasieh K, Silkiss RZ. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2017;33(3):55-57. https://doi.org/10.1097/IOP.0000000000000730
Pérez-Moreiras JV, Álvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant Graves’ orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162-167. https://doi.org/10.1097/IOP.0000000000000037
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018; 195:181-190. https://doi.org/10.1016/j.ajo.2018.07.038
Atienza-Mateo B, Calvo-Río V, Martín-Varillas JL, et al. SAT0601 Anti-il6-receptor tocilizumab in graves’ orbitopathy. multicenter study of 29 patients. Ann Rheum Dis. 2018(77):1153.2-1154. https://doi.org/10.1136/annrheumdis-2018-eular.4830
Copperman T, Idowu OO, Kersten RC, Vagefi MR. Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery. Ophthalmic Plast Reconstr Surg. 2019;35(3):64-66. https://doi.org/10.1097/IOP.0000000000001346
Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy. Am J Ophthalmol Case Reports. 2017;7: 146-148. https://doi.org/10.1016/j.ajoc.2017.07.001
Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415-419. https://doi.org/10.1097/IOP.0000000000000211
Durrani OM, Reuser TQ, Murray PI. Infliximab: A novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24(2):117-119. https://doi.org/10.1080/01676830590912562
Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, Kłysik A, Goś R, Majos A, Stefańczyk L, Stepień H. Monoclonal anti-TNFalpha Antibody (Infliximab) in the Treatment of Patient With Thyroid Associated Ophthalmopathy. Klin Oczna. 2007;109(10-12):457-460.